Compare EH & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EH | IRWD |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 866.0M | 741.8M |
| IPO Year | 2019 | 2009 |
| Metric | EH | IRWD |
|---|---|---|
| Price | $11.17 | $3.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 5 |
| Target Price | ★ $21.85 | $4.94 |
| AVG Volume (30 Days) | 499.0K | ★ 3.0M |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $10.53 | $57.95 |
| Revenue Next Year | $81.37 | $4.39 |
| P/E Ratio | ★ N/A | $21.63 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $11.07 | $0.55 |
| 52 Week High | $23.44 | $5.78 |
| Indicator | EH | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 38.87 | 33.58 |
| Support Level | $11.15 | $3.08 |
| Resistance Level | $12.80 | $3.53 |
| Average True Range (ATR) | 0.58 | 0.26 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 6.35 | 11.70 |
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.